Gilead Pushes Cancer Pipeline; Enters Phase III with PI3K Drug BioWorld Online In the trial, called Study 116, 160 patients at about 70 sites in the US and Europe will be randomized to receive eight infusions of Rituxan (rituximab, Biogen Idec Inc. and Roche AG) over 24 weeks plus GS-1101 or placebo taken orally twice daily. |
